The Use of Secondary Data Analysis Opportunity to produce high-impact research
Maxine Sun, MD Dana-Farber Cancer Institute, discusses The Use of Secondary Data Analysis Opportunity to produce high-impact research at Kidney Cancer Association 2017 in Miami.
Author: kidneycancer
Added: 04/03/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 3, 2018 Category: Cancer & Oncology Source Type: podcasts
Safety and efficacy of axitinib in combination with pembrolizumab in patients with advanced renal cell cancer
Michael B. Atkins, MD Deputy Director Professor, Oncology & Medicine Georgetown Lombardi Comprehensive Cancer Center discusses the efficacy of axitinib in combination with pembrolizumab in patients wi...
Author: Cancer-News
Added: 03/28/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 28, 2018 Category: Cancer & Oncology Source Type: podcasts
Several Elements Factor into Rising Drug Costs Time, development, and innovation adds value to drug costs
Robert Uzzo, MD Fox Chase Cancer Center, discusses Several Elements Factor into Rising Drug Costs Time, development, and innovation adds value to drug costs at Kidney Cancer Association 2017 in Miami...
Author: kidneycancer
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Papillary Kidney Cancer SWOG 1500 - Multiple MET Kinase Inhibitors
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Papillar...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Nivolumab + Ipilimumab Front Line bevacizumab atezolizumab
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares thoughts on Nivoluma...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Cabozantinib + Atezolizumab looks promising in kidney cancer
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, shares how Cabozantinib...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Bladder Cancer Immunotherapy or Chemo Immunotherapy 25-50 Chemo 50-75
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, talks about Bladder Cancer ...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Adjuvant Therapy in Kidney Cancer steering toward immunotherapies in the future
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, explains Adjuvant therapy i...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Adjuvant Immunotherapy Trial may be preferable to Adjuvant therapy in Kidney Cancer
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, explains how the Adjuvant i...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Advances in Immunotherapy for GU Cancers: Focus on Renal Cell Carcinoma
Sumanta (Monty) Kumar Pal, M.D. Associate Clinical Professor, Department of Medical Oncology & Therapeutics Research Co-director, Kidney Cancer Program, Medical Oncologist, provides an in-depth lo...
Author: moasc
Added: 03/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - March 6, 2018 Category: Cancer & Oncology Source Type: podcasts
Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real world data of the availability of new drugs
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Geographic Outcomes of Metastatic RCC in Canada & Europe ESMO-MCBS shows real world data of the availability of new drugs at Kidney Cancer ...
Author: kidneycancer
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 23, 2018 Category: Cancer & Oncology Source Type: podcasts
Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov to see which are currently accruing
Tian Zhang, MD Duke University Medical Center, discusses Many VEGF Phase 3 Trials Have Completed Accrual Colleagues can visit clinicaltrials.gov to see which are currently accruing at Kidney Cancer A...
Author: kidneycancer
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive but still deliver value
Robert Uzzo, MD Fox Chase Cancer Center, discusses Physician-Directed Patient-Oriented Improvements How physicians can deliver the best care & cost-intensive but still deliver value at Kidney Cancer A...
Author: kidneycancer
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery of high value quality-based care
Robert Uzzo, MD Fox Chase Cancer Center, discusses Economic Research and Value in Kidney Cancer Value incentivizes provider & delivery of high value quality-based care at Kidney Cancer Association 201...
Author: kidneycancer
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival
Aly-Khan Lalani, MD Dana Farber Cancer Institute, discusses Sunitinib V. Pazopanib in the First Line Setting Patients receiving sunitinib had better overall survival at Kidney Cancer Association 201...
Author: kidneycancer
Added: 02/22/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 22, 2018 Category: Cancer & Oncology Source Type: podcasts
